1. Search Result
Search Result
Results for "

ATP inhibitor

" in MedChemExpress (MCE) Product Catalog:

844

Inhibitors & Agonists

5

Screening Libraries

8

Fluorescent Dye

6

Biochemical Assay Reagents

5

Peptides

65

Natural
Products

4

Isotope-Labeled Compounds

4

Click Chemistry

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-150983

    ATP Synthase Bacterial Infection
    ATP synthase inhibitor 2 is a Pseudomonas aeruginosa (PA) ATP synthase inhibitor (IC50=10 μg/mL). ATP synthase inhibitor 2 can inhibit Pseudomonas aeruginosa (PA) ATP synthesis activity completely at 128 μg/mL .
    ATP synthase inhibitor 2
  • HY-112715

    ATP Synthase Cardiovascular Disease
    ATP synthase inhibitor 1 is a potent inhibitor of c subunit of the F1/FO-ATP synthase complex, inhibits mitochondrial permeability transition pore (mPTP) opening, does not affect ATP levels .
    ATP synthase inhibitor 1
  • HY-145946

    Epigenetic Reader Domain Cancer
    BRM/BRG1 ATP Inhibitor-2 is a BRG1/BRM ATPase inhibitor for the research of BAF-related disorders.
    BRM/BRG1 ATP Inhibitor-2
  • HY-119374
    BRM/BRG1 ATP Inhibitor-1
    15+ Cited Publications

    Epigenetic Reader Domain Cancer
    BRM/BRG1 ATP Inhibitor-1 (compound 14) is an orally active allosteric dual brahma homolog (BRM)/SWI/SNF related matrix associated actin dependent regulator of chromatin subfamily A member 2 (SMARCA2) and brahma related gene 1 (BRG1)/SMARCA4 ATPase activity inhibitor, both IC50s are below 0.005 µM. BRM/BRG1 ATP Inhibitor-1 has anticancer activity .
    BRM/BRG1 ATP Inhibitor-1
  • HY-162804

    Bacterial ATP Synthase Infection
    ATP synthase inhibitor 3 (compound PT6) is an orally active inhibitor of mycobacterial F-ATP synthase (IC50=0.788 μM). ATP synthase inhibitor 3 inhibits the growth of Mycobacterium tuberculosis H37Rv strain (ATCC-27294) in vitro and depletes intracellular ATP levels at an IC50 value of 30μM .
    ATP synthase inhibitor 3
  • HY-150983A

    ATP Synthase Bacterial Infection
    ATP synthase inhibitor 2 (Compound 22) TFA is a Pseudomonas aeruginosa (PA) ATP synthase inhibitor (IC50=10 μg/mL). ATP synthase inhibitor 2 TFA can inhibit Pseudomonas aeruginosa (PA) ATP synthesis activity completely at 128 μg/mL .
    ATP synthase inhibitor 2 TFA
  • HY-148373

    Epigenetic Reader Domain Cancer
    BRM/BRG1 ATP Inhibitor-3 is a BRG1/BRM inhibitor. BRM/BRG1 ATP Inhibitor-3 inhibits BRM and BRG1 with IC50 values of 10.4 nM and 19.3 nM, respectively. BRM/BRG1 ATP Inhibitor-3 can be used for the research of cancers and BAF complex-related disorders .
    BRM/BRG1 ATP Inhibitor-3
  • HY-148374

    Epigenetic Reader Domain Cancer
    BRM/BRG1 ATP Inhibitor-4 is a BRG1/BRM inhibitor. BRM/BRG1 ATP Inhibitor-4 can be used for the research of cancers and BAF complex-related disorders .
    BRM/BRG1 ATP Inhibitor-4
  • HY-157046

    Bacterial ATP Synthase Infection
    ATP Synthesis-IN-2 (Compound 5) is an antibacterial compound. ATP Synthesis-IN-2 is a potent ATP synthesis activity inhibitor with IC50 against Pseudomonas aeruginosa (PA) Value of 0.7 μg/mL .
    ATP Synthesis-IN-2
  • HY-149736

    PKA ATP Synthase Cardiovascular Disease
    ATP Synthesis-IN-3 (compound 31) is an ATP hydrolysis inhibitor with protective effects during myocardial ischemia. ATP Synthesis-IN-3 can increase the ATP content of ischemic cardiomyocytes, increase the phosphorylation of PKA and phospholamban, and inhibit ischemia-induced apoptosis .
    ATP Synthesis-IN-3
  • HY-134290

    Topoisomerase Cancer
    8-Chloro-ATP, an ATP (HY-B2176) analog, is a topoisomerase II (Topo II) inhibitor. 8-Chloro-ATP inhibits DNA synthesis and induces DNA double-stranded breaks (DSBs). 8-Chloro-ATP inhibits Topo II-catalyzed ATP hydrolysis .
    8-Chloro-ATP
  • HY-134290A

    Topoisomerase Cancer
    8-Chloro-ATP tetrasodium, an ATP (HY-B2176) analog, is a topoisomerase II (Topo II) inhibitor. 8-Chloro-ATP tetrasodium inhibits DNA synthesis and induces DNA double-stranded breaks (DSBs). 8-Chloro-ATP tetrasodium inhibits Topo II-catalyzed ATP hydrolysis .
    8-Chloro-ATP tetrasodium
  • HY-125147

    NAMPT Cancer
    A-1293201 is a substrate-independent NAMPT inhibitor with antitumor activity. A-1293201 effectively reduces the total cellular NAD +/NADH (NADt) level, subsequently leading to ATP depletion and cancer cell death. In addition, A-1293201 can effectively overcome the acquired resistance mechanism of the NAMPT Y18 mutant to CHS-828 (HY-10079) .
    A-1293201
  • HY-114858

    Casein Kinase Cancer
    Epiblastin A is an ATP competitive casein kinase 1 (CK1) inhibitor with IC50s of 8.9, 0.5, and 4.7 µM for CK1α, CK1δ, and CK1 ɛ, respectively. Epiblastin A induces reprogramming of epiblast stem cells into embryonic stem cells by inhibition of CK1 .
    Epiblastin A
  • HY-134031

    DNA/RNA Synthesis Others
    Ara-ATP, a structural analog of ATP, inhibits poly(A) polymerase activity by competing with ATP .
    Ara-ATP
  • HY-N2522
    Carboxyatractyloside dipotassium
    2 Publications Verification

    Gummiferin dipotassium

    Others Others
    Carboxyatractyloside dipotassium is a toxic natural product, acts as an inhibitor of ADP/ATP carrier, inhibits mitochondrial ADP/ATP transport .
    Carboxyatractyloside dipotassium
  • HY-131760

    2'-Amino-2'-deoxyadenosine-5'-triphosphate, 2′-Amino-2′-deoxy-ATP

    Others Metabolic Disease
    2'-NH2-ATP (2'-Amino-2'-deoxyadenosine-5'-triphosphate), an adenosine derivative, is a weak competitive inhibitor of ATP, with a Ki of 2.3 mM. 2'-NH2-ATP can be used in nucleic acid labeling .
    2'-NH2-ATP
  • HY-157045

    ATP Synthase Infection
    ATP Synthesis-IN-1 (Compound 4), quinoline derivative, is a potent inhibitor of PA ATP synthesis activity. ATP Synthesis-IN-1 has PA ATP synthesis inhibition with IC50 value of 11.1μg/mL. ATP Synthesis-IN-1 also has antibacterial activity. ATP Synthesis-IN-1 can be used for the research of drug-resistant PA infection .
    ATP Synthesis-IN-1
  • HY-137888A

    oATP trisodium salt

    P2X Receptor NOD-like Receptor (NLR) Inflammation/Immunology
    Oxidized ATP (oATP) trisodium salt is a broad-spectrum P2 receptor inhibitor. Oxidized ATP trisodium salt irreversibly antagonizes P2X7R activation. Oxidized ATP trisodium salt inhibits c-reactive protein (CRP)-induced NLRP3 inflammasome activation. Oxidized ATP trisodium salt can be used for research of atherosclerosis .
    Oxidized ATP trisodium salt
  • HY-131800

    Others Metabolic Disease
    3'-Deoxy-3'-amino-ATP, an ATP analogue, is a potent and competitive inhibitor of ATP, with a Ki of 2.3 μM. 3'-Deoxy-3'-amino-ATP can be used to synthesis of 3′-Amino-3′-deoxy transfer RNA by incorporation into the 3' terminus of tRNA-C-C .
    3'-Deoxy-3'-amino-ATP
  • HY-N2522R

    Others Others
    Carboxyatractyloside (dipotassium) (Standard) is the analytical standard of Carboxyatractyloside (dipotassium). This product is intended for research and analytical applications. Carboxyatractyloside dipotassium is a toxic natural product, acts as an inhibitor of ADP/ATP carrier, inhibits mitochondrial ADP/ATP transport .
    Carboxyatractyloside dipotassium (Standard)
  • HY-137418

    2-Methylthio-ATP

    P2Y Receptor Others Inflammation/Immunology
    2-MeS-ATP (2-Methylthio-ATP) is an analog of adenosine nucleotides and acts as a P2Y purinergic receptor agonist specific for adenosine nucleotide activation. 2-MeS-ATP is also able to inhibit the release of toxic mediators from macrophages stimulated by endotoxin (LPS). 2-MeS-ATP can be used in the study of endotoxin shock and inflammatory diseases .
    2-MeS-ATP
  • HY-160687

    VEGFR Others
    GW549390X is a dual inhibitor of Fluc and VEGFR2 with IC50 of 0.26 μM and 1.2 μM, respectively. GW549390X can bind to the ATP pocket of FLuc through the aniline side chain and is an ATP-competitive inhibitor of Fluc. GW549390X acts as a protein kinase inhibitor across ATP-dependent and -independent luciferases, with potential implications for Fluc reporter assays .
    GW549390X
  • HY-15513
    TC-DAPK 6
    5+ Cited Publications

    DAPK Cancer
    TC-DAPK 6 is a potent, ATP-competitive, and highly selective DAPK inhibitor (IC50=69 and 225 nM against DAPK1 and DAPK3, respectively, with 10 μM ATP).
    TC-DAPK 6
  • HY-146388

    Bacterial ATP Synthase Infection
    Mtb ATP synthase-IN-1 (compound 6ab) is a potent Mycobacterium tuberculosis (Mtb) ATP synthase inhibitor, with MIC of 0.452-0.499 μg/mL against Mtb. Mtb ATP synthase-IN-1 has good metabolic stability, low cytotoxicity (Vero IC50 > 64 μg/mL), and acceptable oral bioavailability. Mtb ATP synthase-IN-1 can be used for researching anti-mycobacterium .
    Mtb ATP synthase-IN-1
  • HY-12062
    PD318088
    1 Publications Verification

    MEK Cancer
    PD318088 is a potent, allosteric and non-ATP competitive MEK1/2 inhibitor, an analog of PD184352 (HY-50295). PD318088 binds simultaneously with ATP in a region of the MEK1 active site that is adjacent to the ATP-binding site. PD318088 can be used for cancer research .
    PD318088
  • HY-115741

    Others Neurological Disease Cancer
    3BrB-PP1 is an ATP-competitive analog. 3BrB-PP1 can specifically inhibit the activity of protein kinase with mutations in the ATP-binding pocket (mutation of Thr97 within Sty1’s ATP-binding pocket) .
    3BrB-PP1
  • HY-14256
    BMS-191095
    1 Publications Verification

    Potassium Channel Cardiovascular Disease Neurological Disease
    BMS-191095 is a selective activator of mitochondrial ATP-sensitive potassium (mitoKATP) channels. BMS-191095 inhibits human platelet aggregation by opening mitochondrial K(ATP) channels .
    BMS-191095
  • HY-125637

    Aabomycin A2

    Antibiotic Fungal ATP Synthase Infection
    Venturicidin B (Aabomycin A2) is a macrolide antibiotic isolated from Streptomyces sp., used as an antifungal agent, a potent inhibitor of the mitochondrial F0-ATP synthase complex .
    Venturicidin B
  • HY-118960

    ATP Synthase Cardiovascular Disease
    BMS-199264 hydrochloride is an inhibitor of F1F0 ATP hydrolase (IC50=0.5 μM) without inhibitory effect on F1F0 ATP synthase. BMS-199264 hydrochloride selectively inhibits ATP decline during ischemia to reduces cardiac necrosis. BMS-199264 hydrochloride also enhances the recovery of contractile function following reperfusion .
    BMS-199264 hydrochloride
  • HY-161681

    Guanylate Cyclase Metabolic Disease
    Formycin triphosphate is a fluorescent analogue of ATP which on binding to enzyme active sites exhibits enhanced fluorescence. Formycin triphosphate is an ATP-competitive chicken liver pyruvate carboxylase inhibitor. Formycin triphosphate potentiates atrial natriuretic factor (ANF)-stimulated guanylate cyclase activity with an EC50 at about 90 μM and inhibits ATP-stimulated guanylate cyclase activity with an IC50 at about 100 μM .
    Formycin triphosphate
  • HY-50948
    Bay 65-1942 hydrochloride
    3 Publications Verification

    IKK Inflammation/Immunology
    Bay 65-1942 hydrochloride is an ATP-competitive and selective IKKβ inhibitor.
    Bay 65-1942 hydrochloride
  • HY-N1502
    Carboxyatractyloside tripotassium
    2 Publications Verification

    Gummiferin tripotassium

    Others Cancer
    Carboxyatractyloside (Gummiferin) tripotassium is a toxic natural product, acts as an inhibitor of ADP/ATP carrier, inhibits mitochondrial ADP/ATP transport from the inner mitochondria to the inner mitochondria. Carboxyatractyloside tripotassium can be used for the study of cellular energy metabolism and mitochondrial biology .
    Carboxyatractyloside tripotassium
  • HY-125017
    Bozitinib
    1 Publications Verification

    PLB-1001; CBT-101; Vebreltinib

    c-Met/HGFR Cancer
    Bozitinib (PLB-1001) is a highly selective c-MET kinase inhibitor with blood-brain barrier permeability. Bozitinib (PLB-1001) is a ATP-competitive small-molecule inhibitor, binds to the conventional ATP-binding pocket of the tyrosine kinase superfamily .
    Bozitinib
  • HY-112468

    CDK Cancer
    PNU112455A hydrochloride is an ATP-competitive CDK2 and CDK5 inhibitor. PNU112455A hydrochloride binds to the ATP site of CDK2 and CDK5 with Kms of 3.6 and 3.2 μM, respectively .
    PNU112455A hydrochloride
  • HY-16450
    SB 204990
    10+ Cited Publications

    ATP Citrate Lyase Metabolic Disease
    SB 204990 is a potent and specific inhibitor of ATP citrate lyase (ACLY) enzyme.
    SB 204990
  • HY-17537
    APY29
    5+ Cited Publications

    IRE1 Cancer
    APY29, an ATP-competitive inhibitor, is an allosteric modulator of IRE1α which inhibits IRE1α autophosphorylation by binding to the ATP-binding pocket with IC50 of 280 nM. APY29 acts as a ligand that allosterically activates IRE1α adjacent RNase domain .
    APY29
  • HY-12054A

    Aurora Kinase Autophagy Influenza Virus Parasite Cancer
    Hesperadin hydrochloride is an ATP competitive indolinone inhibitor of Aurora A and B. Hesperadin hydrochloride inhibits Aurora B with an IC50 of 250 nM .
    Hesperadin hydrochloride
  • HY-P1292

    PKG Cancer
    PKG inhibitor peptide is an ATP-competitive inhibitor of cGMP-dependent protein kinase (PKG), with a Ki of 86 μM .
    PKG inhibitor peptide
  • HY-11092
    BMS-509744
    5+ Cited Publications

    Itk Inflammation/Immunology
    BMS-509744 is a potent, selective and ATP competitive Itk inhibitor with an IC50 of 19 nM.
    BMS-509744
  • HY-16461

    (-)-Solenopsin A

    Akt Cardiovascular Disease
    Solenopsin ((-)-Solenopsin A) is an ATP-competitive AKT inhibitor with IC50 value of 10 μM .
    Solenopsin
  • HY-50949

    IKK Inflammation/Immunology
    Bay 65-1942 free base is an ATP-competitive and selective IKKβ inhibitor.
    Bay 65-1942 free base
  • HY-115743

    MAP3K Cancer
    TAK1-IN-3 is a potent ATP-competitive TAK1 inhibitor.
    TAK1-IN-3
  • HY-15269

    mTOR PI3K Cancer
    PP30, a TORKinib, is a potent, selective, and ATP-competitive inhibitor of mTOR with an IC50 of 80 nM.
    PP30
  • HY-112465

    PKA Cancer
    H-8 (dihydrochloride) is a cell-permeable, reversible and ATP-competitive PKA inhibitor .
    H-8 dihydrochloride
  • HY-108605

    Pim Cancer
    PIM1-IN-2 is a potent and ATP competitive Pim-1 inhibitor with a Ki of 91 nM. PIM1-IN-2 targets the ATP-binding kinase hinge region not by forming classical hydrogen bonds .
    PIM1-IN-2
  • HY-P1292A

    PKG Cancer
    PKG inhibitor peptide TFA is an ATP-competitive inhibitor of cGMP-dependent protein kinase (PKG), with a Ki of 86 μM .
    PKG inhibitor peptide TFA
  • HY-136532
    ZT-1a
    1 Publications Verification

    Others Neurological Disease
    ZT-1a is a potent, non-ATP-competitive and selective SPAK inhibitor. ZT-1a inhibits SPAK activity with IC50s of 44.3, 35.0, 46.7 μM at ATP concentrations of 0.01, 0.1 and 1 mM, respectively .
    ZT-1a
  • HY-12382

    Mps1 Cancer
    NMS-P715 is a selective, ATP-competitive inhibitor of MPS1, with an IC50 of 182 nM.
    NMS-P715
  • HY-N11781

    ATP Citrate Lyase Metabolic Disease
    Forrestiacids J is an ATP-citrate lyase (ACL) inhibitor with an IC50 of 2.6 μM .
    Forrestiacids J

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: